IJCEMR

Article http://dx.doi.org/10.26855/ijcemr.2022.10.018

Risk of Liver Cancer in acute Hepatoporphyria Patients: A Meta-Analysis of Cohort Studies

TOTAL VIEWS: 6650

Chen Zhang^*, Yaqian Xiao, Qiaobo Wu

The First Clinical College of Hubei University of Medicine, No. 30, Renmin South Road, Maojian District, Shiyan, Hubei Province, 442000, China.

*Corresponding author: Chen Zhang

Published: November 17,2022

Abstract

Objective: The intention of this meta-analysis was once to elucidate the impact of hepatic porphyrias on the chance of hepatic carcinoma. Methods: For the current study, three databases, PUBMED, EMBASE, and Cochrane Library, were selected for the literature search until July 31, 2022, using the Medical Subject Headings (MeSH) and keywords, and the required cohort studies, case-control studies, and cross-sectional studies would be included. All statistical analyses were performed using Stata statistical software version 16.0. The Funnel plot and Egger's test were used to evaluate publication bias. Results: In total, 4 cohort studies involving 2838 individuals were included in the final analysis. The occurrence of hepatic porphyria was associated with the development of hepatocellular carcinoma (OR=34.738; 95% CI: 19.310-62.494, I²=65.0%, P=0.036). We found that women with acute hepatic porphyria had a significantly higher risk of hepatocellular carcinoma than men after subgroup analysis using gender. For the male group, the combined OR=22.564 (95% CI: 11.532-44.149, I²=29.1%, P=0.235). For the female group, the combined OR=26.032 (95% CI: 0.823-822.467, I²=95.9%, P=0.000). Conclusions: The development of hepatic porphyria increases the occurrence of hepatocellular carcinoma, and hepatic porphyria evidence is an independent risk factor for the development of liver cancer.

Keywords

Tuberculosis, initial treatment of smear-positive, case management

References

[1] Li, X., et al. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer, 2021, 21(9): p. 541-557.

[2] Anwanwan, D., et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer, 2020. 1873(1): p. 188314.

[3] Llovet, J.M., et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2021. 7(1): p. 6.

[4] Yu, L.X. and R.F. Schwabe. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol, 2017, 14(9): p. 527-539.

[5] Wong, M.C., et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep, 2017. 7: p. 45846.

[6] Tang, L.S.Y., et al. Chronic Hepatitis B Infection: A Review. JAMA, 2018. 319(17): p. 1802-1813.

[7] Lin, M.V., L.Y. King, and R.T. Chung. Hepatitis C virus-associated cancer. Annu Rev Pathol, 2015. 10: p. 345-70.

[8] Turati, F., et al. Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol, 2014. 25(8): p. 1526-35.

[9] Larsson, S.C. and A. Wolk. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer, 2007. 97(7): p. 1005-8.

[10] Petrick, J.L., et al. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. Am J Gastroenterol, 2018. 113(10): p. 1494-1505.

[11] Liu, Y., et al. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer, 2012. 48(14): p. 2125-36.

[12] Yang, W.S., et al. Diet and liver cancer risk: a narrative review of epidemiological evidence. Br J Nutr, 2020. 124(3): p. 330-340.

[13] Gerischer, L.M., et al. Acute porphyrias - A neurological perspective. Brain Behav, 2021. 11(11): p. e2389.

[14] Tan, D.J.H., et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver dis-ease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology, 2022. 23(4): p. 521-530.

[15] Xu, X.L., et al. Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Controlled Trials with Meta-Analysis and Trial Sequential Analysis. Radiology, 2018. 287(2): p. 461-472.

[16] Fontanellas, A., et al. Current and innovative emerging therapies for porphyrias with hepatic involvement. J Hepatol, 2019. 71(2): p. 422-433.

[17] Lissing, M., et al. Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals. J Intern Med, 2022. 291(6): p. 824-836.

[18] Baravelli, C.M., et al. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study. Orphanet J Rare Dis, 2019. 14(1): p. 77.

[19] Sardh, E., et al. High risk of primary liver cancer in a cohort of 179 patients with Acute Hepatic Porphyria. J Inherit Metab Dis, 2013. 36(6): p. 1063-71.

[20] Martha S. Linet, G.G., Olof Nyren,Lene Mellemkjaer, Jorgen H. Olsen, Shannon Keehn, HansOlov Adami, and Joseph F. Fraumeni, Jr. Primary Liver Cancer, Other Malignancies, and Mortality Risks following Porphyria: A Cohort Study in Denmark and Sweden. 1999.

[21] Christophe Andant, H.P., Catherine Bogard’, Jean Faivre2, Jean-Claude Soul& Yves Nordmann’ and Jean-Charles Deybach’, Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors 2000.

[22] Seth, A.K., et al. Liver transplantation for porphyria: who, when, and how? Liver Transpl, 2007. 13(9): p. 1219-27.

How to cite this paper

Risk of Liver Cancer in acute Hepatoporphyria Patients: A Meta-Analysis of Cohort Studies

How to cite this paper: Chen Zhang, Yaqian Xiao, Qiaobo Wu. (2022) Risk of Liver Cancer in acute Hepatoporphyria Patients: A Meta-Analysis of Cohort Studies. International Journal of Clinical and Experimental Medicine Research, 6(4), 428-432.

DOI: http://dx.doi.org/10.26855/ijcemr.2022.10.018